Equillium

Equillium is a biotechnology company developing products for autoimmune and inflammatory diseases, or unmet medical needs in immune-inflammatory diseases. Its lead candidate is EQ001, a clinical-stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in T-cell activity, driving many immune-inflammatory diseases such as graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis.